INTRODUCTION
Glaucoma is a chronic progressive optic neuropathy caused by a group of ocular conditions which lead to damage of optic nerve with loss of visual function. 1 Raised intraocular pressure is essentially due to an increased resistance to the circulation of the aqueous at the pupil or to its drainage through the angle of the anterior chamber. 2 Normal intraocular pressure depends up on the formation and outflow of aqueous humour which is under the control of parasympathetic and sympathetic activities of the autonomic nervous system. Normal intraocular pressure is maintained at 10-21mm of Hg. 3 The diagnosis of glaucoma is made after looking for a combination of clinical signs characteristic change in the optic nerve head, abnormalities in visual field and a rise in intraocular pressure. 4 The type of glaucoma is determined by the clinical features and the status of anterior chamber angle as determined by gonioscopy. 5 Primary open angle glaucoma (POAG) characteristically has an adult onset and is a bilateral almost symmetrical disease. Ocular examination shows an open anterior chamber angle, optic nerve head changes, visual field damage and an intraocular pressure of more than 21mm Hg. POAG is the commonest form of glaucoma in Caucasians and Africans. It occurs in the elderly rarely being seen earlier than 40years of age. The inheritance is thought to be multi factorial and polygenic. 6 
Timolol Maleate
It is a non selective β1 and β2 adrenergic antagonist. It reduces intra ocular pressure in normal and glaucomatous eyes without changing the visual acuity and accommodation on pupil size (Katz et al., 1976 , Radius et al., 1978 . 7, 8 It is supplied in 0.25% and 0.5% concentration, which are administered every 12 to 24 hours. It penetrates the eye rapidly and following topical administration IOP begin to fall in ½ to 1 hour, reaches a maximum in 2 hours and returns to baseline in 24 to 48 hours. The aqueous production is reduced to 47% after one week of timolol treatment but only 25% after one year of treatment. This process has been called "Long Term Drift" and is due to a time dependent decrease in acellular sensitivity to adrenergic antagonist.
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Dorzolamide
It is a topically used carbonic anhydrase inhibitor developed to circumvent systemic side effects of acetazolamide. It is available in 2% eye drops. It lowers intra ocular tension by 20%; Ocular stinging, burning sensation, itching, bitter taste are side effects. It causes shallowing of the anterior chamber and leads to transient Myopia. It does not give change in pupil size, no diminution of vision in dim light and in patient with cataract. 10 The present study was undertaken to evaluate and compare the efficacy and side effects of these two drugs in patients with Glaucoma and increased intra ocular pressure. 
METHODS
Study
Statistical analysis
Statistical analysis of data obtained were presented in tabular form. Mean±SD, t value, p value and comparison between groups were done by Graph Pad software. p value <0.05 was considered significant. In Table 3 , mean reduction of IOP after 24 weeks in group IA and Group IB was significant in both the eyes. Mean reduction of IOP after 24 weeks in Group IIA and IIB was not significant in right eye but significant in left eye. In Table 4 , mean reduction of IOP after 24 weeks in Group IA and IIA and Group IB and IIB was significant in both the eyes.
RESULTS
In
In Table 5 There was a significant fall in both systolic and diastolic blood pressure in Dorzolamide group at the end of week 24. But Timolol group showed more significant fall in systolic and diastolic blood pressure at the end of week 24.
In 
DISCUSSION
Timely and adequate control of glaucoma is very important to prevent further silent loss of vision. The treatment of glaucoma is primarily directed towards lowering intra ocular pressure. This can be brought about by conservative medical treatment, laser therapy or by surgery.
In Table 2 Overall the percent reduction at the IOP from the baseline at the end of treatment period was 9.81% at trough and 20.80% at peak drug levels by monotherapy. 11 A. Scardillo reported 20% reduction of IOP after instillation of 2% Dorzolamide hydrochloride three times daily into the conjunctival sac of affected eyes. In another study by Melamed S and David R in 2000 on 46 patients receiving Timolol maleate 0.5% reported a mean IOP reduction of 5.57mm Hg. Also reported a mean reduction of IOP ranged from 5.8 to 6.6mm Hg at 2-hour peak. At 12-hour trough the Timolol group had mean IOP lowering ranging from 3.8 to 4.8 mm Hg. Insufficient responses i.e. the IOP reduction of less than 10% at the end of week 2, was seen in 1 patient in Group IA, 2 patients in Group IB, 1 patient in Group IIA and 2 patients in Group IIB. 2 patients, one from Group IA and other from Group IIA did not turn-up after week 4. All of those patients were excluded from further study.
According to
According to Table 5 , there was significant fall in both systolic and diastolic blood pressure in both the groups. However, fall of mean blood pressure was more in Timolol group than Dorzolamide group. A similar and significant decrease of mean pressure without clinical symptoms were noted by Derick RJ et al. 15 In Table 6 , mean pre-treatment heart rate of 76.75±6.23 beats/min and 78.17±3.12 beats/min in Dorzolamide and Timolol group respectively. At the end of 24 weeks of treatment there was a significant mean reduction of 1.87±1.55 beats/min in Dorzolamide group and 4.0±2.26 beats/ min in Timolol group.
Both drug regimens were well-tolerated, and no serious drug-related adverse effects were reported. In present study 3 patients who were hypertensive and 2 patients who were asthmatic were on Dorzolamide and showed no exaggeration of these systemic problems.
In the present study, ocular burning sensation, ocular stinging sensation and bitter taste were reported significantly and more frequently in patients receiving Dorzolamide hydrochloride 2% while ocular irritation and dryness of mouth reported more often in timolol treated patients. Ellen Strahman et al, reported in 1995, the most frequently reported symptom among patients receiving Dorzolamide was bitter taste (27%) compared with smaller proportion of patients receiving timolol (7%).
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CONCLUSION
Dorzolamide had an edge over Timolol as far as reduction of intra ocular pressure in concerned. Dorzolamide was well-tolerated, low allergic response and had a favourable ocular and systemic safety profile. Dorzolamide had lesser effect on cardiovascular parameters than Timolol and can be used safely in patients with asthmatic and chronic obstructive pulmonary disease.
